Donor BMI >30 Is Not a Contraindication for Live Liver Donation |
| |
| Authors: | A. Doyle M. S. Cattral P. D. Greig L. Lilly I. D. McGilvray G. A. Levy A. Ghanekar E. L. Renner D. R. Grant M. Selzner N. Selzner |
| |
| Affiliation: | 1. Department of Medicine, Multi Organ Transplant Program, Toronto General Hospital, Toronto, ON, Canada;2. Department of Surgery, Multi Organ Transplant Program, Toronto General Hospital, Toronto, ON, Canada |
| |
| Abstract: | The increased prevalence of obesity worldwide threatens the pool of living liver donors. Although the negative effects of graft steatosis on liver donation and transplantation are well known, the impact of obesity in the absence of hepatic steatosis on outcome of living donor liver transplantation (LDLT) is unknown. Consequently, we compared the outcome of LDLT using donors with BMI <30 versus donors with BMI ≥30. Between April 2000 and May 2014, 105 patients received a right‐lobe liver graft from donors with BMI ≥30, whereas 364 recipients were transplanted with grafts from donors with BMI <30. Liver steatosis >10% was excluded in all donors with BMI >30 by imaging and liver biopsies. None of the donors had any other comorbidity. Donors with BMI <30 versus ≥30 had similar postoperative complication rates (Dindo‐Clavien ≥3b: 2% vs. 3%; p = 0.71) and lengths of hospital stay (6 vs. 6 days; p = 0.13). Recipient graft function, assessed by posttransplant peak serum bilirubin and international normalized ratio was identical. Furthermore, no difference was observed in recipient complication rates (Dindo‐Clavien ≥3b: 25% vs. 20%; p = 0.3) or lengths of hospital stay between groups. We concluded that donors with BMI ≥30, in the absence of graft steatosis, are not contraindicated for LDLT. |
| |
| Keywords: | clinical research/practice liver transplantation/hepatology donors and donation: living liver transplantation: living donor |
|
|
